Resistance of rheumatoid arthritis patients to changing therapy: Discordance between disease activity and patients' treatment choices
- 28 June 2007
- journal article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (7), 2135-2142
- https://doi.org/10.1002/art.22719
Abstract
Objective Despite advances in rheumatoid arthritis (RA) treatment, patients' decisions regarding therapy often deviate from expert recommendation. This study was undertaken to investigate patients' acceptance and satisfaction with therapy, willingness to change therapy, and reasons for not changing. Methods Participants (n = 6,135) completed an 11‐item questionnaire concerning treatment preferences. Eight questions assessed reasons for not wanting to change therapy. The contribution of individual predictors was determined by logistic regression analysis. Results Questionnaire responses showed that 63.8% of the patients would not want to change therapy as long as their condition didn't get worse; 77.3% were satisfied with their medications, while 9.4% were dissatisfied. These assessments were weakly related to RA activity and functional status. Side effects had occurred in 22.4% of the patients during the previous 6 months, and in 65.5% at some period during their lifetime. Predictors of unwillingness to change therapy were satisfaction with RA control, which had an odds ratio (OR) of 6.8 (95% confidence interval [95% CI] 5.8–8.0), risk of side effects (OR 4.4 [95% CI 3.8–5.2]), physician opinion (OR 1.9 [95% CI 1.6–2.2]), fear of loss of control (OR 1.8 [95% CI 1.6–2.1]), lack of better medications (OR 1.4 [95% CI 1.2–1.6]), and costs (OR 1.3 [95% CI 1.1–1.6]). There was little difference in results between patients who were receiving biologic agents and those who were not. Conclusion There is substantial discrepancy between declared satisfaction with therapy and measured RA activity and functional status. Most RA patients are satisfied with their therapy, even many with abnormal scores. Fear of loss of control of RA and fear of side effects are major patient concerns. Maintenance of current status, rather than future improvement, appears to be a high priority for patients.Keywords
This publication has 31 references indexed in Scilit:
- Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease‐modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- Treatment of early seropositive rheumatoid arthritis: Doxycycline plus methotrexate versus methotrexate aloneArthritis & Rheumatism, 2006
- Beliefs about medications: a questionnaire survey of people with rheumatoid arthritisRheumatology, 2005
- Disease activity measurement of rheumatoid arthritis: Comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routineArthritis Care & Research, 2005
- The patient's perspective and rheumatoid arthritis disease activity indexesRheumatology, 2004
- Perceptions of the risks and benefits of medicines in patients with rheumatoid arthritis and other painful musculoskeletal conditionsRheumatology, 2004
- Rheumatoid arthritis in 2003: where are we now with treatment?Annals Of The Rheumatic Diseases, 2003
- Attitude of rheumatoid arthritis patients to treatment with oral corticosteroidsRheumatology, 2003
- A self‐administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic researchArthritis & Rheumatism, 1995
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980